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Metformin is currently the first-line treatment option for patients with type 2 diabetes mellitus, yet its mechanism of action remains uncertain. A new study reveals the important role for the activation of a duodenal AMPK-dependent neuronal pathway in the acute antihyperglycaemic effect of metformin and the inhibition of hepatic glucose production.
The prevalence of type 2 diabetes mellitus (T2DM) has reached epidemic proportions worldwide and represents an important threat to global public health systems. On the basis of available clinical evidence, the American Diabetes Association (ADA) reaffirmed metformin as the optimal firstline therapy for patients with T2DM, unless contraindications or intolerance are present. 1 This recommendation was made not only because metformin is easily accessible and affordable, but also because of the longstanding evidence base for its efficacy, safety (low risk of hypoglycaemic episodes) and potential benefits on multiple cardio vascular risk factors.
1,2 However, although metformin has been prescribed for >50 years in Europe (the drug was only approved by the FDA in December 1994), its mechanism of action is still disputed. The action of metformin is probably dependent on a combination of distinct activities, as the potential mechanisms by which this drug has beneficial effects include multiple organs such as the liver and the small intestine.
In the past few years, much of the basic research on metformin has focused on its ability to suppress hepatic glucose production (HGP). Multiple underlying mechanisms with the mitochondria as the primary target have been described. 2 For a decade, metformin-induced inhibition of hepatic gluconeogenesis has been attributed to the activation of the serine/ threonine kinase 11 (STK11)-5' AMP-activated pro tein kinase (AMPK) signalling pathway, which senses cellular energy levels and regulates the balance between catabolic and anabolic processes. However, this mechanism of action has been challenged by the use of liver-specific STK11 (also known as liver kinase B1 [LKB1]) and AMPK knockout mouse models. 3, 4 Findings published in 2010 further established that metformin functions via AMPKindependent mechanisms to lower HGP. 3 Indeed, metformin-dependent inhibition of the mitochondrial electron transport complex I triggers a decrease in the cellular ATP:AMP ratio, which results in low levels of ATP that are insufficient to drive energyconsuming hepatic gluco neogenesis. 3 In addition, a metformin-induced increase in AMP levels leads to the inhibition of adenylate cyclase and of the induction of gluco neogenesis by glucagon. 4 AMP is also a potent allosteric inhibitor of fructose 1,6-bisphosphatase, a key enzyme in gluco neogenesis. Furthermore, inhibition of glycerol-3-phosphate dehydro genase in the mitochondria results in an altered cellular redox state and limits the contribution of lactate and glycerol to hepatic gluco neogenesis. 5 The intestine also contributes to the overall glucose-lowering effect of metformin and might be an important site of action of this drug. 6 Increased intestinal use of glucose, which enhances anaerobic metabolism of glucose to lac tate, increases glucose turnover and sup ports the anti hyperglycaemic action of the drug. In addition, it should be noted that oral dosing induces a stronger and longer g lucose-lowering response than metformin administered intravenously and metformin accumulates in the intestinal mucosa to a greater extent than it does in the liver, which supports the notion that the gastrointestinal tract is an important target organ for metformin. 6 The recent study reported by Duca et al. 7 proposes a new paradigm for the diverse modes of action of metformin. Previous findings had highlighted the importance of nutrient sensing in the gut for triggering a neuronal negative-feedback system for glucose homeostasis. Duca and coworkers went on to show that metformin in the duodenal lumen (that has not yet been absorbed) reduces HGP through a gutbrain-liver neuronal network. 7 This effect was observed when metformin (50 mg kg -1 or 200 mg kg -1 ) was infused directly into the duodenal lumen of insulin-resistant rats, but not when it was delivered via the portal vein. By using a combination of pharmacological approaches, Duca et al. uncovered the cellular mechanisms underlying the action of metformin on intestinal mucosa and subsequent inhibition of HGP.
Duca and colleagues attribute the effect of duodenal infusion of metformin to the release of glucagon-like peptide 1 (GLP-1), probably from enteroendocrine L cells, and activation of the GLP-1 receptor (GLP1R) on the afferent vagus nerve innervating the small intestine to trigger a gut-brain-liver axis that regulates HGP (Figure 1 ). The investigators hypothesize that metformininduced activation of AMPK in the intestinal mucosa could stimulate the release of GLP-1. This theory is consistent with other findings that metformin and the AMPK agonist acadesine (also known as 5-aminoimidazole-4-carboxamide 1-β-dribofuranoside) are GLP-1 secretagogues. 8 Duca et al. infected the duodenum of in sulin-resistant rats with an adenovirus encoding a dominant-negative mutated form of AMPK, which showed that duodenal AMPK is required for the preabsorptive action of metformin. However, it was not possible to determine the specific '' …metformin-induced activation of AMPK in the intestinal mucosa could stimulate the release of GLP-1 '' co ntribution of cells that produce GLP-1 and/or other cell types in the therapeutic benefit of metformin-induced activation of AMPK. In addition, it remains unclear whether locally produced GLP-1 (acting directly on close afferent neurons) and/ or enhanced circulating levels of GLP-1 (for distant hor monal actions) are a prerequisite for the acute therapeutic effect of metformin. Unfortunately, the study lacks information on plasma levels of GLP-1 during and after intraduodenal treatment.
The researchers show that the signal to release GLP-1 induced by metformin is relayed by the activation of GLP1R on vagal afferent neurons through effects on a neuronal network. This action was demonstrated by co-infusion with the GLP1R antagonist exendin-9, chemical denervation and vagotomy that completely eliminated the effects of metformin in the duodenum on HGP. Curiously, this result contrasts with a previous report demonstrating that the acute glucoregulatory actions of metformin are independent of GLP1R. 8 Further elucidation of the mechanisms underlying the action of metformin in the duodenum will benefit from animal models that target AMPK and intestinal signalling molecules.
One intriguing question raised by this work is the contribution of the acute action of metformin in the duodenum in clinical settings, in which patients are usually exposed to metformin for long periods of time. Interestingly, an increasing amount of evidence suggests that metformin 'shapes' the metabolic plasticity of the gastro intestinal tract by inducing alterations in the recirculation of bile acids and the composition of the gut microbiota, which results in enhanced GLP-1 secretion in patients with T2DM. 9 Thus, acute and chronic gl ucoselowering effects of metformin might be largely mediated by a combination of in testinal and direct hepatic mechanisms.
Collectively, these results provide compelling evidence that metformin targets a duodenal AMPK-dependent neuronal network to regulate HGP. A major implication of these findings is that AMPK could be a primary therapeutic target within the intestine to restore impaired glu cose homeostasis in patients with T2DM. Interest ingly, Duca and co-workers showed that intraduodenal infusion of the small molecule AMPK activator A-769662 mimicked the effect of intraduodenal metformin infusion. 7 Of note, activation of duodenal AMPK with the polyphenol resveratrol also initiates a gut-brain-liver axis to reduce HGP. 10 Whether these new insights could lead to therapeutic strategies in humans remains to be determined. 
